PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 6814427-7 1982 Deficiency of acid ceramidase activity in fibroblasts from patients with Farber disease and intermediate activities in obligate heterozygotes were demonstrated with all ceramides examined except for N-hexanoylsphingosine (C(6:0)/C(18:1)), whereas alkaline ceramidase activity was unaffected. N-caproylsphingosine 199-220 N-acylsphingosine amidohydrolase 1 Homo sapiens 14-29 32178876-0 2020 C6-ceramide induces salivary adenoid cystic carcinoma cell apoptosis via IP3R-activated UPR and UPR-independent pathways. N-caproylsphingosine 0-11 inositol 1,4,5-trisphosphate receptor type 3 Homo sapiens 73-77 32746845-0 2020 C6-ceramide treatment inhibits the proangiogenic activity of multiple myeloma exosomes via the miR-29b/Akt pathway. N-caproylsphingosine 0-11 microRNA 29b-1 Homo sapiens 95-102 32746845-0 2020 C6-ceramide treatment inhibits the proangiogenic activity of multiple myeloma exosomes via the miR-29b/Akt pathway. N-caproylsphingosine 0-11 AKT serine/threonine kinase 1 Homo sapiens 103-106 32746845-6 2020 RESULTS: Our results showed that exosomes released from MM cells treated by C6-cer (ExoC6-cer) significantly inhibited the proliferation, migration and tube formation of ECs. N-caproylsphingosine 76-82 exocyst complex component 6 Homo sapiens 84-89 32374916-9 2021 C6-Ceramide, an analogue of natural ceramide, competed with C24-Ceramide for PIP4K2C binding, thereby abrogating C24-Ceramide -mediated mTOR signaling activation and oncogenic activity. N-caproylsphingosine 0-11 phosphatidylinositol-5-phosphate 4-kinase type 2 gamma Homo sapiens 77-84 32374916-9 2021 C6-Ceramide, an analogue of natural ceramide, competed with C24-Ceramide for PIP4K2C binding, thereby abrogating C24-Ceramide -mediated mTOR signaling activation and oncogenic activity. N-caproylsphingosine 0-11 mechanistic target of rapamycin kinase Homo sapiens 136-140 32374916-10 2021 Furthermore, stimulation with C6-Ceramide significantly suppressed the proliferative and metastatic capacity of GBC cells in vitro and in vivo, which was dependent on PIP4K2C. N-caproylsphingosine 30-41 phosphatidylinositol-5-phosphate 4-kinase type 2 gamma Homo sapiens 167-174 32374916-12 2021 We propose that PIP4K2C is indispensable for C6-Ceramide as potential therapeutic intervention for GBC through a direct competition with C24-Ceramide. N-caproylsphingosine 45-56 phosphatidylinositol-5-phosphate 4-kinase type 2 gamma Homo sapiens 16-23 32829707-11 2020 RESULTS: The expression of MMP-9, p-JAK2 and p-STAT3 in BEAS-2B cells was significantly increased after the treatment of C6-ceramide. N-caproylsphingosine 121-132 matrix metallopeptidase 9 Homo sapiens 27-32 32829707-11 2020 RESULTS: The expression of MMP-9, p-JAK2 and p-STAT3 in BEAS-2B cells was significantly increased after the treatment of C6-ceramide. N-caproylsphingosine 121-132 Janus kinase 2 Homo sapiens 36-40 32829707-11 2020 RESULTS: The expression of MMP-9, p-JAK2 and p-STAT3 in BEAS-2B cells was significantly increased after the treatment of C6-ceramide. N-caproylsphingosine 121-132 signal transducer and activator of transcription 3 Homo sapiens 47-52 32829707-12 2020 Furthermore, the increased expression of MMP-9 induced by C6-ceramide was inhibited by AG490 and Stattic. N-caproylsphingosine 58-69 matrix metallopeptidase 9 Homo sapiens 41-46 31898284-5 2020 To elucidate potential mechanism, a specific ERK1/2 activator (ceramide C6) was administered prior to Met-RANTES treatment; CCR1 activator (recombinant CCL5, rCCL5) and TPR1 CRISPR were administered in naive mouse. N-caproylsphingosine 63-74 mitogen-activated protein kinase 3 Mus musculus 45-51 32178876-4 2020 In our study, gene expression microarray was used to discover that the unfolded protein response (UPR) pathway, especially PRKR-like endoplasmic reticulum kinase (PERK) pathway, was the major activated pathway after treatment of c6-ceramide. N-caproylsphingosine 229-240 eukaryotic translation initiation factor 2 alpha kinase 3 Homo sapiens 123-161 32178876-4 2020 In our study, gene expression microarray was used to discover that the unfolded protein response (UPR) pathway, especially PRKR-like endoplasmic reticulum kinase (PERK) pathway, was the major activated pathway after treatment of c6-ceramide. N-caproylsphingosine 229-240 eukaryotic translation initiation factor 2 alpha kinase 3 Homo sapiens 163-167 32178876-6 2020 We found that inositol 1,4,5-trisphosphate receptor 3 (IP3R3) was activated, leading to Ca2+ release from ER, soon after c6-ceramide treatment. N-caproylsphingosine 121-132 inositol 1,4,5-trisphosphate receptor type 3 Homo sapiens 55-60 32229586-10 2020 Consistently, inhibition of ABCC-mediated transport reduced the efflux of exogenous C6-ceramide. N-caproylsphingosine 84-95 ATP binding cassette subfamily C member 1 Homo sapiens 28-32 31112736-6 2019 Using the human AML cell line KG-1, we demonstrate that, unlike exposure to the single agents, combination C6-ceramide-tamoxifen upregulated LC3-II expression, inhibited the mTOR signaling pathway, and synergistically induced KG-1 cell death in an Atg5-dependent manner. N-caproylsphingosine 107-118 autophagy related 5 Homo sapiens 248-252 30836822-5 2019 Treatment with C6-ceramide nanoliposomes (CNL) resulted in a preferential increase in C16-ceramide and suppressed SNAI2 transcriptional activation and protein expression. N-caproylsphingosine 15-26 snail family transcriptional repressor 2 Homo sapiens 114-119 30154232-6 2018 Cells overexpressing nCDase were protected from the cell death and Golgi fragmentation induced by C6-ceramide, and they showed reduced levels of C6-ceramide and higher levels of S1P and sphingosine. N-caproylsphingosine 98-109 N-acylsphingosine amidohydrolase 2 Homo sapiens 21-27 30154232-6 2018 Cells overexpressing nCDase were protected from the cell death and Golgi fragmentation induced by C6-ceramide, and they showed reduced levels of C6-ceramide and higher levels of S1P and sphingosine. N-caproylsphingosine 145-156 N-acylsphingosine amidohydrolase 2 Homo sapiens 21-27 28858294-5 2018 In this study, we showed that C6 ceramide (an exogenous ceramide supplement, 1.25-40 mumol/L) dose-dependently inhibited the proliferation and promoted the apoptosis in human MM OPM2 cell line, which were associated with elevated caspase 3/9 and PARP cleavage. N-caproylsphingosine 30-41 caspase 3 Homo sapiens 230-241 29968910-5 2018 PKC412 decreased Akt-mammalian target of rapamycin (mTOR) activation in HNSCC cells, facilitated with cotreatment of C6 ceramide. N-caproylsphingosine 117-128 mechanistic target of rapamycin kinase Homo sapiens 52-56 29357287-0 2018 Interaction of KRas4B protein with C6-ceramide containing lipid model membranes. N-caproylsphingosine 35-46 KRAS proto-oncogene, GTPase Homo sapiens 15-21 29357287-4 2018 C6-ceramide has been shown to inhibit the growth activity of KRas4B mutated cells. N-caproylsphingosine 0-11 KRAS proto-oncogene, GTPase Homo sapiens 61-67 29357287-11 2018 A FRET-based binding assay reveals that the stability of KRas4B proteins inserted into the membrane containing C6-ceramide is reduced. N-caproylsphingosine 111-122 KRAS proto-oncogene, GTPase Homo sapiens 57-63 29357287-12 2018 Based on the combined results obtained, we postulate a molecular mechanism for the inhibition of KRas4B mutated cells" activity through C6-ceramide. N-caproylsphingosine 136-147 KRAS proto-oncogene, GTPase Homo sapiens 97-103 28858294-5 2018 In this study, we showed that C6 ceramide (an exogenous ceramide supplement, 1.25-40 mumol/L) dose-dependently inhibited the proliferation and promoted the apoptosis in human MM OPM2 cell line, which were associated with elevated caspase 3/9 and PARP cleavage. N-caproylsphingosine 30-41 collagen type XI alpha 2 chain Homo sapiens 246-250 28858294-6 2018 We also found that C6 ceramide (5-20 mumol/L) dose-dependently stimulated exosome secretion and increased exosomal levels of tumor-suppressive miRs (miR 202, miR 16, miR 29b and miR 15a). N-caproylsphingosine 19-30 microRNA 202 Homo sapiens 149-156 28858294-6 2018 We also found that C6 ceramide (5-20 mumol/L) dose-dependently stimulated exosome secretion and increased exosomal levels of tumor-suppressive miRs (miR 202, miR 16, miR 29b and miR 15a). N-caproylsphingosine 19-30 glycerophosphodiester phosphodiesterase 1 Homo sapiens 158-164 28858294-6 2018 We also found that C6 ceramide (5-20 mumol/L) dose-dependently stimulated exosome secretion and increased exosomal levels of tumor-suppressive miRs (miR 202, miR 16, miR 29b and miR 15a). N-caproylsphingosine 19-30 microRNA 29b-1 Homo sapiens 166-173 28858294-6 2018 We also found that C6 ceramide (5-20 mumol/L) dose-dependently stimulated exosome secretion and increased exosomal levels of tumor-suppressive miRs (miR 202, miR 16, miR 29b and miR 15a). N-caproylsphingosine 19-30 microRNA 15a Homo sapiens 178-185 28189725-2 2017 Earlier works using the ceramide analog, C6-ceramide, demonstrated that the antiestrogen tamoxifen, a first generation P-glycoprotein (P-gp) inhibitor, blocked C6-ceramide glycosylation and magnified apoptotic responses. N-caproylsphingosine 41-52 ATP binding cassette subfamily B member 1 Homo sapiens 119-133 29263930-0 2017 STAT3 mediates C6-ceramide-induced cell death in chronic lymphocytic leukemia. N-caproylsphingosine 15-26 signal transducer and activator of transcription 3 Mus musculus 0-5 28189725-4 2017 Herein we demonstrate that the tamoxifen metabolites, desmethyltamoxifen and didesmethyltamoxifen, and specific, high-affinity P-gp inhibitors, tariquidar and zosuquidar, synergistically enhanced C6-ceramide cytotoxicity in multidrug resistant HL-60/VCR acute myelogenous leukemia (AML) cells, whereas the selective estrogen receptor antagonist, fulvestrant, was ineffective. N-caproylsphingosine 196-207 ATP binding cassette subfamily B member 1 Homo sapiens 127-131 28189725-5 2017 Active C6-ceramide-adjuvant combinations elicited mitochondrial ROS production and cytochrome c release, and induced apoptosis. N-caproylsphingosine 7-18 cytochrome c, somatic Homo sapiens 83-95 28189725-10 2017 Given the active properties of these adjuvants in synergizing with C6-ceramide, independent of drug resistance status, stemness, or cancer type, our results suggest that the C6-ceramide-containing regimens could provide alternative, promising therapeutic direction, in addition to finding novel, off-label applications for P-gp inhibitors. N-caproylsphingosine 174-185 ATP binding cassette subfamily B member 1 Homo sapiens 323-327 28189725-2 2017 Earlier works using the ceramide analog, C6-ceramide, demonstrated that the antiestrogen tamoxifen, a first generation P-glycoprotein (P-gp) inhibitor, blocked C6-ceramide glycosylation and magnified apoptotic responses. N-caproylsphingosine 41-52 ATP binding cassette subfamily B member 1 Homo sapiens 135-139 28189725-2 2017 Earlier works using the ceramide analog, C6-ceramide, demonstrated that the antiestrogen tamoxifen, a first generation P-glycoprotein (P-gp) inhibitor, blocked C6-ceramide glycosylation and magnified apoptotic responses. N-caproylsphingosine 160-171 ATP binding cassette subfamily B member 1 Homo sapiens 119-133 28189725-2 2017 Earlier works using the ceramide analog, C6-ceramide, demonstrated that the antiestrogen tamoxifen, a first generation P-glycoprotein (P-gp) inhibitor, blocked C6-ceramide glycosylation and magnified apoptotic responses. N-caproylsphingosine 160-171 ATP binding cassette subfamily B member 1 Homo sapiens 135-139 27539961-3 2016 We herein demonstrated for the first time that GlcCer synthase activity for the fluorescent ceramide, 4-nitrobenzo-2-oxa-1,3-diazole-labeled C6-ceramide (NBD-ceramide) increased in intact NPC1((-/-)) cells and cell lysates without affecting the protein levels. N-caproylsphingosine 141-152 NPC intracellular cholesterol transporter 1 Homo sapiens 188-192 27045476-6 2016 Exposure of cells to C6-ceramide (24 h) promoted a dose-dependent (2.5-10 microM) decrease in the expression of cell surface beta1 and beta4 integrin subunits in all cell lines; at 10 microM C6-ceramide, the decreases ranged from 30 to 50% of the control. N-caproylsphingosine 21-32 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 125-130 27562715-3 2016 We show that co-treatment of C6 ceramide dramatically potentiated AT406-induced caspase/apoptosis activation and cytotoxicity in established (Panc-1 and Mia-PaCa-2 lines) and primary human pancreatic cancer cells. N-caproylsphingosine 29-40 pancreas protein 1 Mus musculus 142-148 27562715-7 2016 In vivo, liposomal C6 ceramide plus AT406 co-administration dramatically inhibited Panc-1 xenograft tumor growth in severe combined immunodeficient (SCID) mice. N-caproylsphingosine 19-30 pancreas protein 1 Mus musculus 83-89 26364609-4 2016 The bioactive sphingolipid ceramide has emerged as an antitumorigenic lipid, and treatment with short-chain C6-ceramide decreased the number of ovarian cancer cells with PI3KC2beta-driven lamellipodia. N-caproylsphingosine 108-119 phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 beta Homo sapiens 170-180 26220867-10 2015 Treatment of Molt-3, an acute lymphoblastic leukemia cell line, with 4-HPR revealed moderate ceramide production (5-fold over control), robust conversion of ceramide to GC and sphingomyelin, and resistance to 4-HPR and C6-ceramide. N-caproylsphingosine 219-230 haptoglobin-related protein Homo sapiens 71-74 26599810-6 2015 Low-dose (1 muM) treatment with C6-Cer favoured conversion of the precursor to sphingomyelin, whereas higher concentrations (25-100 muM) yielded increased conversion to C6-glucosylceramide. N-caproylsphingosine 32-38 latexin Homo sapiens 12-15 26318452-6 2015 In addition, exogenously added C6-ceramide mimicked the effects of TNFalpha that lead to cell death, which were inhibited by fumonisin B1. N-caproylsphingosine 31-42 tumor necrosis factor Homo sapiens 67-75 25080062-12 2015 In SCCKN and UV 2 cells, C6-ceramide suppressed the expressions of VEGF, VEGF receptor-2, and HIF-1alpha in vitro. N-caproylsphingosine 25-36 vascular endothelial growth factor A Mus musculus 67-71 25080062-12 2015 In SCCKN and UV 2 cells, C6-ceramide suppressed the expressions of VEGF, VEGF receptor-2, and HIF-1alpha in vitro. N-caproylsphingosine 25-36 vascular endothelial growth factor A Mus musculus 73-77 25080062-12 2015 In SCCKN and UV 2 cells, C6-ceramide suppressed the expressions of VEGF, VEGF receptor-2, and HIF-1alpha in vitro. N-caproylsphingosine 25-36 hypoxia-inducible factor 1-alpha Cricetulus griseus 94-104 25305563-5 2014 In this work, we propose the active intracellular delivery of combinations of doxorubicin and the pro-apoptotic sphingolipid, C6-ceramide, using our previously described cytosolic triggered release-enabling liposomes, targeting nucleolin with the F3 peptide. N-caproylsphingosine 126-137 nucleolin Homo sapiens 228-237 26089893-8 2015 Inhibition of PLD by a general antagonist (1-butanol) or specific inhibitor, halopemide, or N-hexanoylsphingosine, or by cellular ceramides accumulated in doxorubicin-treated hepatocytes decreased insulin-stimulated glucose metabolism. N-caproylsphingosine 92-113 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 14-17 24025258-3 2013 We have investigated the effect of the small chain C6-ceramide, known to be a bioactive tumor suppressor lipid, on I2PP2A function, thereby affecting c-Myc signaling and histone acetylation in cells. N-caproylsphingosine 51-62 SET nuclear proto-oncogene Homo sapiens 115-121 24367685-6 2013 In CLL cells, we demonstrate that C6-ceramide nanoliposomes, but not control nanoliposomes, induce caspase 3/7-independent necrotic cell death. N-caproylsphingosine 34-45 caspase 3 Mus musculus 99-108 24048885-7 2013 The ceramide analogue, C6-ceramide, induced a decrease in decidual cell viability and of p38 MAPK phosphorylation. N-caproylsphingosine 23-34 mitogen activated protein kinase 14 Rattus norvegicus 89-92 24048885-9 2013 Furthermore, AEA and C6-ceramide induced a drop in DeltaPsim, an increase in ROS production and caspase-3/-7 activation, effects partially reverted by inhibitors of ceramide synthesis and of p38 MAPK. N-caproylsphingosine 21-32 caspase 3 Rattus norvegicus 96-105 24048885-9 2013 Furthermore, AEA and C6-ceramide induced a drop in DeltaPsim, an increase in ROS production and caspase-3/-7 activation, effects partially reverted by inhibitors of ceramide synthesis and of p38 MAPK. N-caproylsphingosine 21-32 mitogen activated protein kinase 14 Rattus norvegicus 191-194 24298430-3 2013 In this study, we have used label-free Raman micro-spectral analysis and kinetic modeling to study cellular interactions and intracellular delivery of C6-ceramide using a non-targeted and an epidermal growth factor receptor (EGFR) targeted biodegradable polymeric nano-delivery systems, in EGFR-expressing human ovarian adenocarcinoma (SKOV3) cells. N-caproylsphingosine 151-162 epidermal growth factor receptor Homo sapiens 225-229 24735534-6 2014 Finally, we found that C6 ceramide enhanced curcumin-induced cytotoxicity probably through facilitating mPTP opening, while CsA and SfA as well as CyPD and ANT-1 siRNAs alleviated C6 ceramide"s effect on curcumin in WM-115 cells. N-caproylsphingosine 180-191 peptidylprolyl isomerase F Homo sapiens 147-151 24735534-6 2014 Finally, we found that C6 ceramide enhanced curcumin-induced cytotoxicity probably through facilitating mPTP opening, while CsA and SfA as well as CyPD and ANT-1 siRNAs alleviated C6 ceramide"s effect on curcumin in WM-115 cells. N-caproylsphingosine 180-191 solute carrier family 25 member 4 Homo sapiens 156-161 25280528-5 2014 Experiments testing a potential role for C6-ceramide-mediated effects on activation of protein kinase C (PKC) demonstrated evidence for signaling through the calcium-independent isoform, PKCepsilon. N-caproylsphingosine 41-52 protein kinase C, gamma Rattus norvegicus 87-103 25280528-5 2014 Experiments testing a potential role for C6-ceramide-mediated effects on activation of protein kinase C (PKC) demonstrated evidence for signaling through the calcium-independent isoform, PKCepsilon. N-caproylsphingosine 41-52 protein kinase C, gamma Rattus norvegicus 105-108 25280528-6 2014 We employed 2-dimensional electrophoresis and anti-phospho-peptide antibodies to test whether treatment of the cardiomyocytes with C6-ceramide altered myocyte shortening via PKC-dependent phosphorylation of myofilament proteins. N-caproylsphingosine 131-142 protein kinase C, gamma Rattus norvegicus 174-177 23793993-5 2013 Synergistic cytotoxic effects between DOX and bioactive lipid C6-ceramide in P-gp overexpressing drug resistant leukemia P388/ADR cells were observed. N-caproylsphingosine 62-73 phosphoglycolate phosphatase Mus musculus 77-81 24025258-3 2013 We have investigated the effect of the small chain C6-ceramide, known to be a bioactive tumor suppressor lipid, on I2PP2A function, thereby affecting c-Myc signaling and histone acetylation in cells. N-caproylsphingosine 51-62 MYC proto-oncogene, bHLH transcription factor Homo sapiens 150-155 24025258-5 2013 C6-ceramide was able to disrupt the association between PP2A and I2PP2A. N-caproylsphingosine 0-11 protein phosphatase 2 phosphatase activator Homo sapiens 56-60 24025258-5 2013 C6-ceramide was able to disrupt the association between PP2A and I2PP2A. N-caproylsphingosine 0-11 SET nuclear proto-oncogene Homo sapiens 65-71 24025258-6 2013 C6-ceramide inhibits I2PP2A"s upregulation of c-Myc and downregulation of histone acetylation in prostate cancer cells. N-caproylsphingosine 0-11 SET nuclear proto-oncogene Homo sapiens 21-27 24025258-6 2013 C6-ceramide inhibits I2PP2A"s upregulation of c-Myc and downregulation of histone acetylation in prostate cancer cells. N-caproylsphingosine 0-11 MYC proto-oncogene, bHLH transcription factor Homo sapiens 46-51 22615346-6 2012 Further characterization was performed with PP2Calpha, which showed robust activation by C(6)-ceramide. N-caproylsphingosine 89-102 protein phosphatase, Mg2+/Mn2+ dependent 1A Homo sapiens 44-53 23181473-5 2013 Thus, we treated both rat and human leukemic NK cells in combination with: (1) exogenous C6-ceramide nanoliposomes in order to target mitochondria and increase physiological pro-apoptotic levels of long chain ceramide, and (2) 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol (PPMP), an inhibitor of GCS. N-caproylsphingosine 89-100 UDP-glucose ceramide glucosyltransferase Homo sapiens 301-304 23353700-4 2013 Because intracellular P-glycoprotein (P-gp) plays a role in catalyzing the conversion of ceramide to higher sphingolipids, we hypothesized that administration of P-gp antagonists with C6-ceramide would magnify cell death cascades. N-caproylsphingosine 184-195 ATP binding cassette subfamily B member 1 Homo sapiens 22-36 23353700-4 2013 Because intracellular P-glycoprotein (P-gp) plays a role in catalyzing the conversion of ceramide to higher sphingolipids, we hypothesized that administration of P-gp antagonists with C6-ceramide would magnify cell death cascades. N-caproylsphingosine 184-195 ATP binding cassette subfamily B member 1 Homo sapiens 38-42 23353700-4 2013 Because intracellular P-glycoprotein (P-gp) plays a role in catalyzing the conversion of ceramide to higher sphingolipids, we hypothesized that administration of P-gp antagonists with C6-ceramide would magnify cell death cascades. N-caproylsphingosine 184-195 ATP binding cassette subfamily B member 1 Homo sapiens 162-166 22954799-10 2012 Thus exposure to sphingomyelinase or C6-ceramide triggers eryptosis followed by phosphatidylserine- and CXCL16-sensitive adhesion of eryptotic erythrocytes to HUVEC. N-caproylsphingosine 37-48 C-X-C motif chemokine ligand 16 Homo sapiens 104-110 23038012-7 2012 In cells treated with 4-nitrobenzo-2-oxa-1,3-diazole (NBD)-labeled C6-ceramide, Hsp90 inhibitors reduced the formation of NBD-glucosylceramide and Na(3)VO(4)-induced formation of NBD-caproic acid, a counterpart of sphingosine, without affecting other metabolites including NBD-sphingomyelin. N-caproylsphingosine 67-78 heat shock protein 90 alpha family class A member 1 Rattus norvegicus 80-85 24319543-2 2012 In the present investigation, we observed that C6-ceramide induces p53-dependent apoptosis and effectively killed the Astrocytoma grade4 (Glioblastoma Multiforme) HTB12 cell lines. N-caproylsphingosine 47-58 tumor protein p53 Homo sapiens 67-70 22100336-7 2012 We further show that changes in alternative splicing of hnRNP A/B, affected by up regulation of SRSF5 (SRp40) or by treatment with C6-ceramide, occur within supraspliceosomes. N-caproylsphingosine 131-142 heterogeneous nuclear ribonucleoprotein A/B Homo sapiens 56-65 21396934-8 2011 Further, whereas C6-ceramide and cyc A imparted 1.5- and 0-fold increases in caspase 3/7 activity, the combination produced a 3.5-fold increase. N-caproylsphingosine 17-28 caspase 3 Homo sapiens 77-86 21278235-9 2011 Inhibition of ceramide synthase with fumonisin B1 prevented p53 reactivation induced by GCS silencing, whereas addition of exogenous C6-ceramide reactivated p53 function in p53-mutant cells. N-caproylsphingosine 133-144 tumor protein p53 Homo sapiens 157-160 21193455-4 2011 METHODS: The growth-arresting and pro-apoptotic properties of nanoliposomal C6-ceramide were first evaluated in vitro in human SK-HEP-1 cells by assessing cellular viability, caspase 3/7 activity, annexin-V expression, DNA fragmentation, cell cycle distribution and AKT phosphorylation. N-caproylsphingosine 76-87 caspase 3 Homo sapiens 175-184 21193455-4 2011 METHODS: The growth-arresting and pro-apoptotic properties of nanoliposomal C6-ceramide were first evaluated in vitro in human SK-HEP-1 cells by assessing cellular viability, caspase 3/7 activity, annexin-V expression, DNA fragmentation, cell cycle distribution and AKT phosphorylation. N-caproylsphingosine 76-87 AKT serine/threonine kinase 1 Homo sapiens 266-269 21193455-7 2011 RESULTS: Nanoliposomal C6-ceramide, but not ghost (no ceramide) nanoliposomes, induced apoptotic cell death of SK-HEP-1 cells in vitro, concomitant with an accumulation of cells in the G2 phase of the cell cycle and decreased phosphorylation of AKT. N-caproylsphingosine 23-34 AKT serine/threonine kinase 1 Homo sapiens 245-248 21193455-8 2011 Systemic administration of nanoliposomal C6-ceramide to mice engrafted with SK-HEP-1 tumours reduced tumour vascularisation and proliferation, induced tumour cell apoptosis, decreased phosphorylation of AKT and ultimately blocked tumour growth. N-caproylsphingosine 41-52 thymoma viral proto-oncogene 1 Mus musculus 203-206 21278235-9 2011 Inhibition of ceramide synthase with fumonisin B1 prevented p53 reactivation induced by GCS silencing, whereas addition of exogenous C6-ceramide reactivated p53 function in p53-mutant cells. N-caproylsphingosine 133-144 tumor protein p53 Homo sapiens 157-160 19165630-13 2010 Genetic expression of peroxisome proliferator-activated receptor (PPAR) gamma and aP2 in D1 cells was reduced by C6-ceramide treatment. N-caproylsphingosine 113-124 peroxisome proliferator activated receptor alpha Mus musculus 22-64 21368888-0 2011 C6-ceramide synergistically potentiates the anti-tumor effects of histone deacetylase inhibitors via AKT dephosphorylation and alpha-tubulin hyperacetylation both in vitro and in vivo. N-caproylsphingosine 0-11 thymoma viral proto-oncogene 1 Mus musculus 101-104 21368888-4 2011 TSA interacts in a highly synergistic manner with C6-ceramide to disrupt HDAC6/protein phosphatase 1 (PP1)/tubulin complex, to induce alpha-tubulin hyperacetylation, and to release and activate PP1, which then leads to AKT dephosphorylation and eventually causes cancer cell death. N-caproylsphingosine 50-61 protein phosphatase 1 catalytic subunit gamma Mus musculus 73-100 21368888-4 2011 TSA interacts in a highly synergistic manner with C6-ceramide to disrupt HDAC6/protein phosphatase 1 (PP1)/tubulin complex, to induce alpha-tubulin hyperacetylation, and to release and activate PP1, which then leads to AKT dephosphorylation and eventually causes cancer cell death. N-caproylsphingosine 50-61 protein phosphatase 1 catalytic subunit gamma Mus musculus 102-105 21368888-4 2011 TSA interacts in a highly synergistic manner with C6-ceramide to disrupt HDAC6/protein phosphatase 1 (PP1)/tubulin complex, to induce alpha-tubulin hyperacetylation, and to release and activate PP1, which then leads to AKT dephosphorylation and eventually causes cancer cell death. N-caproylsphingosine 50-61 protein phosphatase 1 catalytic subunit gamma Mus musculus 194-197 21368888-4 2011 TSA interacts in a highly synergistic manner with C6-ceramide to disrupt HDAC6/protein phosphatase 1 (PP1)/tubulin complex, to induce alpha-tubulin hyperacetylation, and to release and activate PP1, which then leads to AKT dephosphorylation and eventually causes cancer cell death. N-caproylsphingosine 50-61 thymoma viral proto-oncogene 1 Mus musculus 219-222 21647331-3 2011 The aim of this study was to potentiate the effect of ceramide as anti-angiogenic compound that can regulate tumor induced angiogenesis.C6-ceramide inhibited vascular endothelial growth factor (VEGF)-induced human umbilical vein endothelial cells (HUVEC) tube formation in a dose-dependent manner within 24 hours. N-caproylsphingosine 136-147 vascular endothelial growth factor A Homo sapiens 158-192 21647331-3 2011 The aim of this study was to potentiate the effect of ceramide as anti-angiogenic compound that can regulate tumor induced angiogenesis.C6-ceramide inhibited vascular endothelial growth factor (VEGF)-induced human umbilical vein endothelial cells (HUVEC) tube formation in a dose-dependent manner within 24 hours. N-caproylsphingosine 136-147 vascular endothelial growth factor A Homo sapiens 194-198 21042729-2 2010 The purpose of this investigation was to evaluate the role of P-glycoprotein (P-gp) in regulating ceramide cytotoxicity by using C6-ceramide. N-caproylsphingosine 129-140 ATP binding cassette subfamily B member 1 Homo sapiens 62-76 21042729-2 2010 The purpose of this investigation was to evaluate the role of P-glycoprotein (P-gp) in regulating ceramide cytotoxicity by using C6-ceramide. N-caproylsphingosine 129-140 ATP binding cassette subfamily B member 1 Homo sapiens 78-82 21042729-4 2010 HeLa cells expressing P-gp (P-gp/on cells) challenged with [14C]C6-ceramide (6 microM), synthesized 4.5-fold the amount of C6-glucosylceramide (GC) compared to HeLa cells with suppressed expression of P-gp (P-gp/off cells), whereas the generated levels of C6-sphingomyelin were almost equal (33 and 29% of intracellular 14C, respectively). N-caproylsphingosine 64-75 ATP binding cassette subfamily B member 1 Homo sapiens 22-26 21042729-4 2010 HeLa cells expressing P-gp (P-gp/on cells) challenged with [14C]C6-ceramide (6 microM), synthesized 4.5-fold the amount of C6-glucosylceramide (GC) compared to HeLa cells with suppressed expression of P-gp (P-gp/off cells), whereas the generated levels of C6-sphingomyelin were almost equal (33 and 29% of intracellular 14C, respectively). N-caproylsphingosine 64-75 ATP binding cassette subfamily B member 1 Homo sapiens 28-32 21042729-4 2010 HeLa cells expressing P-gp (P-gp/on cells) challenged with [14C]C6-ceramide (6 microM), synthesized 4.5-fold the amount of C6-glucosylceramide (GC) compared to HeLa cells with suppressed expression of P-gp (P-gp/off cells), whereas the generated levels of C6-sphingomyelin were almost equal (33 and 29% of intracellular 14C, respectively). N-caproylsphingosine 64-75 ATP binding cassette subfamily B member 1 Homo sapiens 28-32 21042729-4 2010 HeLa cells expressing P-gp (P-gp/on cells) challenged with [14C]C6-ceramide (6 microM), synthesized 4.5-fold the amount of C6-glucosylceramide (GC) compared to HeLa cells with suppressed expression of P-gp (P-gp/off cells), whereas the generated levels of C6-sphingomyelin were almost equal (33 and 29% of intracellular 14C, respectively). N-caproylsphingosine 64-75 ATP binding cassette subfamily B member 1 Homo sapiens 28-32 21042729-8 2010 In the cytotoxicity assays, the P-gp/off cells were sensitive to C6-ceramide and the P-gp/on cells were resistant. N-caproylsphingosine 65-76 ATP binding cassette subfamily B member 1 Homo sapiens 32-36 21042729-9 2010 Resistance to C6-ceramide in the P-gp/on cells was reversed by tamoxifen but not by ethylenedioxy-P4. N-caproylsphingosine 14-25 ATP binding cassette subfamily B member 1 Homo sapiens 33-37 21042729-11 2010 This study demonstrates that P-gp potentiates C6-ceramide glycosylation and if antagonized augments C6-ceramide sensitivity, both features previously ascribed to GCS. N-caproylsphingosine 46-57 ATP binding cassette subfamily B member 1 Homo sapiens 29-33 21042729-11 2010 This study demonstrates that P-gp potentiates C6-ceramide glycosylation and if antagonized augments C6-ceramide sensitivity, both features previously ascribed to GCS. N-caproylsphingosine 100-111 UDP-glucose ceramide glucosyltransferase Homo sapiens 162-165 19576658-6 2010 Interestingly, C6-ceramide inhibited the phosphorylation of CD29 induced by MEM101A treatment and down-regulated surface levels of CD29, CD98, and CD147, as well as CD49d. N-caproylsphingosine 15-26 integrin subunit beta 1 Homo sapiens 60-64 19576658-6 2010 Interestingly, C6-ceramide inhibited the phosphorylation of CD29 induced by MEM101A treatment and down-regulated surface levels of CD29, CD98, and CD147, as well as CD49d. N-caproylsphingosine 15-26 integrin subunit beta 1 Homo sapiens 131-135 19576658-6 2010 Interestingly, C6-ceramide inhibited the phosphorylation of CD29 induced by MEM101A treatment and down-regulated surface levels of CD29, CD98, and CD147, as well as CD49d. N-caproylsphingosine 15-26 solute carrier family 3 member 2 Homo sapiens 137-141 19576658-6 2010 Interestingly, C6-ceramide inhibited the phosphorylation of CD29 induced by MEM101A treatment and down-regulated surface levels of CD29, CD98, and CD147, as well as CD49d. N-caproylsphingosine 15-26 basigin (Ok blood group) Homo sapiens 147-152 19576658-6 2010 Interestingly, C6-ceramide inhibited the phosphorylation of CD29 induced by MEM101A treatment and down-regulated surface levels of CD29, CD98, and CD147, as well as CD49d. N-caproylsphingosine 15-26 integrin subunit alpha 4 Homo sapiens 165-170 20375276-5 2010 In the present study we examined the effects of cell-permeable C(6)-ceramide on HERG potassium channels stably expressed in HEK-293 cells. N-caproylsphingosine 63-76 potassium voltage-gated channel subfamily H member 2 Homo sapiens 80-84 20375276-6 2010 C(6)-ceramide (10 microM) reversibly inhibited HERG channel current (I(HERG)) by 36 +/- 5%. N-caproylsphingosine 0-13 potassium voltage-gated channel subfamily H member 2 Homo sapiens 47-51 20375276-6 2010 C(6)-ceramide (10 microM) reversibly inhibited HERG channel current (I(HERG)) by 36 +/- 5%. N-caproylsphingosine 0-13 potassium voltage-gated channel subfamily H member 2 Homo sapiens 71-75 20375276-11 2010 Our results provide new insights into the effects of C(6)-ceramide on HERG channels and suggest that C(6)-ceramide can be a promising therapeutic for cancers that overexpress HERG. N-caproylsphingosine 53-66 potassium voltage-gated channel subfamily H member 2 Homo sapiens 70-74 20375276-11 2010 Our results provide new insights into the effects of C(6)-ceramide on HERG channels and suggest that C(6)-ceramide can be a promising therapeutic for cancers that overexpress HERG. N-caproylsphingosine 101-114 potassium voltage-gated channel subfamily H member 2 Homo sapiens 70-74 20375276-11 2010 Our results provide new insights into the effects of C(6)-ceramide on HERG channels and suggest that C(6)-ceramide can be a promising therapeutic for cancers that overexpress HERG. N-caproylsphingosine 101-114 potassium voltage-gated channel subfamily H member 2 Homo sapiens 175-179 19165630-13 2010 Genetic expression of peroxisome proliferator-activated receptor (PPAR) gamma and aP2 in D1 cells was reduced by C6-ceramide treatment. N-caproylsphingosine 113-124 peroxisome proliferator activated receptor alpha Mus musculus 66-70 19165630-13 2010 Genetic expression of peroxisome proliferator-activated receptor (PPAR) gamma and aP2 in D1 cells was reduced by C6-ceramide treatment. N-caproylsphingosine 113-124 transcription factor AP-2, alpha Mus musculus 82-85 19165630-14 2010 CCAAT/enhancer-binding protein (C/EBP) beta levels in D1 cells were reduced by C6-ceramide treatment during early differentiation; PPARgamma and aP2 protein levels were reduced at terminal differentiation. N-caproylsphingosine 79-90 CCAAT/enhancer binding protein (C/EBP), beta Mus musculus 32-43 19707468-6 2008 The purified Pak1 demonstrated autophosphorylation in vitro that was enhanced by D-erythro-sphingosine-1, N-acetyl-D-erythro-sphingosine (C(2)-ceramide), and N-hexanoyl-D-erythro-sphingosine (C(6)-ceramide). N-caproylsphingosine 158-190 p21 (RAC1) activated kinase 1 Bos taurus 13-17 19107118-6 2009 We also observed that radiation-induced AC upregulation was sufficient to create cross-resistance to chemotherapy as demonstrated by decreased sensitivity to Taxol and C(6) ceramide compared to controls. N-caproylsphingosine 168-181 N-acylsphingosine amidohydrolase 1 Homo sapiens 40-42 19029119-3 2009 Here we show that short-chain ceramides (C(2)-ceramide and C(6)-ceramide) and stimulation of the de novo ceramide synthesis by tamoxifen induce the dissociation of the complex formed between the autophagy protein Beclin 1 and the anti-apoptotic protein Bcl-2. N-caproylsphingosine 59-72 beclin 1 Homo sapiens 213-221 19029119-3 2009 Here we show that short-chain ceramides (C(2)-ceramide and C(6)-ceramide) and stimulation of the de novo ceramide synthesis by tamoxifen induce the dissociation of the complex formed between the autophagy protein Beclin 1 and the anti-apoptotic protein Bcl-2. N-caproylsphingosine 59-72 BCL2 apoptosis regulator Homo sapiens 253-258 19707468-6 2008 The purified Pak1 demonstrated autophosphorylation in vitro that was enhanced by D-erythro-sphingosine-1, N-acetyl-D-erythro-sphingosine (C(2)-ceramide), and N-hexanoyl-D-erythro-sphingosine (C(6)-ceramide). N-caproylsphingosine 192-205 p21 (RAC1) activated kinase 1 Bos taurus 13-17 18188632-3 2008 The results of the present study demonstrate that natural (CerPCho, C18-ceramide) and synthetic (C6-ceramide) sphingolipids reduced PC-3 cell proliferation by 15 +/- 1.8, 17 +/- 2.5, and 46 +/- 2.1%, respectively (P < 0.05). N-caproylsphingosine 97-108 BTG anti-proliferation factor 2 Homo sapiens 132-136 18948750-3 2008 C6-ceramide induces cleavage of Caspase-8 and Caspase-9, but only Caspase-8 is required for apoptosis. N-caproylsphingosine 0-11 caspase 8 Homo sapiens 32-41 18948750-3 2008 C6-ceramide induces cleavage of Caspase-8 and Caspase-9, but only Caspase-8 is required for apoptosis. N-caproylsphingosine 0-11 caspase 9 Homo sapiens 46-55 18948750-6 2008 While C6-ceramide can activate PP2A in acute leukemia cells, the sphingolipid did not activate the phosphatase in K562 cells. N-caproylsphingosine 6-17 protein phosphatase 2 phosphatase activator Homo sapiens 31-35 18948750-7 2008 C6-ceramide did not activate p38 kinase but did promote JNK activation and phosphorylation of JUN. N-caproylsphingosine 0-11 mitogen-activated protein kinase 8 Homo sapiens 56-59 18948750-8 2008 Inhibition of JNK by pharmacological agent protected K562 cells from C6-ceramide suggesting that JNK plays an essential role in C6-ceramide mediated apoptosis. N-caproylsphingosine 69-80 mitogen-activated protein kinase 8 Homo sapiens 14-17 18948750-8 2008 Inhibition of JNK by pharmacological agent protected K562 cells from C6-ceramide suggesting that JNK plays an essential role in C6-ceramide mediated apoptosis. N-caproylsphingosine 69-80 mitogen-activated protein kinase 8 Homo sapiens 97-100 18948750-8 2008 Inhibition of JNK by pharmacological agent protected K562 cells from C6-ceramide suggesting that JNK plays an essential role in C6-ceramide mediated apoptosis. N-caproylsphingosine 128-139 mitogen-activated protein kinase 8 Homo sapiens 14-17 18948750-8 2008 Inhibition of JNK by pharmacological agent protected K562 cells from C6-ceramide suggesting that JNK plays an essential role in C6-ceramide mediated apoptosis. N-caproylsphingosine 128-139 mitogen-activated protein kinase 8 Homo sapiens 97-100 18245173-9 2008 Exogenous C(6)-ceramide and sphingomyelinase treatments mimicked the influence of doxorubicin on GCS, activating the GCS promoter and up-regulating GCS gene expression. N-caproylsphingosine 10-23 UDP-glucose ceramide glucosyltransferase Homo sapiens 97-100 18245173-9 2008 Exogenous C(6)-ceramide and sphingomyelinase treatments mimicked the influence of doxorubicin on GCS, activating the GCS promoter and up-regulating GCS gene expression. N-caproylsphingosine 10-23 UDP-glucose ceramide glucosyltransferase Homo sapiens 117-120 18245173-9 2008 Exogenous C(6)-ceramide and sphingomyelinase treatments mimicked the influence of doxorubicin on GCS, activating the GCS promoter and up-regulating GCS gene expression. N-caproylsphingosine 10-23 UDP-glucose ceramide glucosyltransferase Homo sapiens 117-120 18188632-5 2008 Treatment of PC-3 cells with CerPCho and C18-ceramide significantly increased apoptosis by 3.0 +/- 0.8 and 3.6 +/- 0.6%, respectively, compared to the untreated control, while the synthetic C6-ceramide significantly increased apoptosis by 55.7 +/- 0.4%. N-caproylsphingosine 190-201 BTG anti-proliferation factor 2 Homo sapiens 13-17 18188632-6 2008 C6-ceramide-induced apoptosis was associated with cell cycle arrest in the G(2)/M phase, decreased extracellular signal-regulated kinase (ERK1/2) signaling and activation of the cell cycle regulatory protein, retinoblastoma (pRb). N-caproylsphingosine 0-11 mitogen-activated protein kinase 3 Homo sapiens 138-144 18188632-6 2008 C6-ceramide-induced apoptosis was associated with cell cycle arrest in the G(2)/M phase, decreased extracellular signal-regulated kinase (ERK1/2) signaling and activation of the cell cycle regulatory protein, retinoblastoma (pRb). N-caproylsphingosine 0-11 RB transcriptional corepressor 1 Homo sapiens 209-223 18188632-6 2008 C6-ceramide-induced apoptosis was associated with cell cycle arrest in the G(2)/M phase, decreased extracellular signal-regulated kinase (ERK1/2) signaling and activation of the cell cycle regulatory protein, retinoblastoma (pRb). N-caproylsphingosine 0-11 RB transcriptional corepressor 1 Homo sapiens 225-228 17521618-10 2007 C6-ceramide further diminished protein levels of protooncogenes c-myc (p<0.05) and ODC (p<0.01), which is strictly related to the ability of ceramides to inhibit cell growth in a time- and dose-dependent manner. N-caproylsphingosine 0-11 MYC proto-oncogene, bHLH transcription factor Homo sapiens 64-69 17596294-9 2007 Apoptosis mediated by C(6)-ceramide at 24 h is significantly reduced by caspase-3 inhibition, which supports cross talk between calpain- and caspase-dependent apoptotic pathways. N-caproylsphingosine 22-35 caspase 3 Homo sapiens 72-81 17881906-6 2007 Moreover, using the MTS viability assay, AC-EGFP cells were more resistant to cell death induced by doxorubicin, cisplatin, etoposide, gemcitabine or C6-ceramide. N-caproylsphingosine 150-161 N-acylsphingosine amidohydrolase 1 Homo sapiens 41-43 17521618-10 2007 C6-ceramide further diminished protein levels of protooncogenes c-myc (p<0.05) and ODC (p<0.01), which is strictly related to the ability of ceramides to inhibit cell growth in a time- and dose-dependent manner. N-caproylsphingosine 0-11 ornithine decarboxylase 1 Homo sapiens 86-89 17308302-1 2007 We have previously demonstrated that hexanoyl-D-erythro-sphingosine (C(6)-ceramide), an anti-mitogenic cell-permeable lipid metabolite, limited vascular smooth muscle growth by abrogating trauma-induced Akt activity in a stretch injury model of neointimal hyperplasia. N-caproylsphingosine 69-82 AKT serine/threonine kinase 1 Rattus norvegicus 203-206 17426710-5 2007 Next, comparison of three HNSCC cell lines with low, medium, and high levels of AC reveals an inverse correlation between the levels of AC and their response to exogenous C-6-ceramide. N-caproylsphingosine 171-183 N-acylsphingosine amidohydrolase 1 Homo sapiens 80-82 17426710-5 2007 Next, comparison of three HNSCC cell lines with low, medium, and high levels of AC reveals an inverse correlation between the levels of AC and their response to exogenous C-6-ceramide. N-caproylsphingosine 171-183 N-acylsphingosine amidohydrolase 1 Homo sapiens 136-138 17308302-4 2007 Using rat aorta vascular smooth muscle cells (A7r5), we now demonstrate that C(6)-ceramide treatment results in an increased localization and phosphorylation of PKC zeta within caveolin-enriched lipid microdomians to inactivate Akt. N-caproylsphingosine 77-90 AKT serine/threonine kinase 1 Rattus norvegicus 228-231 17213336-8 2007 The expression of PLD1 mRNA transcripts was selectively decreased by C6-ceramide, and increased by ceramide synthesis inhibitors. N-caproylsphingosine 69-80 phospholipase D1 Mus musculus 18-22 15563986-6 2004 The application of 1 microM C6-ceramide for 36 h reduced PPARgamma mRNA level, aP2 mRNA level, and PPARgamma protein level to 56.3%, 80.4% and 62.1%, respectively. N-caproylsphingosine 28-39 transcription factor AP-2 alpha Homo sapiens 79-82 16170023-0 2005 Resistance to TRAIL is associated with defects in ceramide signaling that can be overcome by exogenous C6-ceramide without requiring down-regulation of cellular FLICE inhibitory protein. N-caproylsphingosine 103-114 TNF superfamily member 10 Homo sapiens 14-19 15951564-2 2005 The activity of the N-terminal truncated hTERT promoter, lacking the c-Myc recognition (E-box) region but containing multiple Sp1/Sp3 sites, was also significantly inhibited by C6-ceramide, indicating a role for ceramide in the regulation of Sp1/Sp3 function. N-caproylsphingosine 177-188 telomerase reverse transcriptase Homo sapiens 41-46 15951564-2 2005 The activity of the N-terminal truncated hTERT promoter, lacking the c-Myc recognition (E-box) region but containing multiple Sp1/Sp3 sites, was also significantly inhibited by C6-ceramide, indicating a role for ceramide in the regulation of Sp1/Sp3 function. N-caproylsphingosine 177-188 Sp3 transcription factor Homo sapiens 130-133 15951564-2 2005 The activity of the N-terminal truncated hTERT promoter, lacking the c-Myc recognition (E-box) region but containing multiple Sp1/Sp3 sites, was also significantly inhibited by C6-ceramide, indicating a role for ceramide in the regulation of Sp1/Sp3 function. N-caproylsphingosine 177-188 Sp3 transcription factor Homo sapiens 246-249 15951564-4 2005 Treatment with C6-ceramide inhibited the trans-activation function of overexpressed Sp1, whereas it induced the repressor effects of exogenous Sp3 on the hTERT promoter. N-caproylsphingosine 15-26 Sp3 transcription factor Homo sapiens 143-146 15951564-4 2005 Treatment with C6-ceramide inhibited the trans-activation function of overexpressed Sp1, whereas it induced the repressor effects of exogenous Sp3 on the hTERT promoter. N-caproylsphingosine 15-26 telomerase reverse transcriptase Homo sapiens 154-159 15951564-6 2005 In contrast, the promoter DNA-binding activity of Sp3 was slightly increased in response to C6-ceramide, resulting in the increased ratio of Sp3/Sp1 on the hTERT promoter, which was concomitant with the reduced recruitment of RNA polymerase II to the promoter. N-caproylsphingosine 92-103 Sp3 transcription factor Homo sapiens 50-53 15951564-6 2005 In contrast, the promoter DNA-binding activity of Sp3 was slightly increased in response to C6-ceramide, resulting in the increased ratio of Sp3/Sp1 on the hTERT promoter, which was concomitant with the reduced recruitment of RNA polymerase II to the promoter. N-caproylsphingosine 92-103 Sp3 transcription factor Homo sapiens 141-144 15951564-6 2005 In contrast, the promoter DNA-binding activity of Sp3 was slightly increased in response to C6-ceramide, resulting in the increased ratio of Sp3/Sp1 on the hTERT promoter, which was concomitant with the reduced recruitment of RNA polymerase II to the promoter. N-caproylsphingosine 92-103 telomerase reverse transcriptase Homo sapiens 156-161 15951564-8 2005 Mechanistically, the data demonstrated that C6-ceramide reduced the acetylation of Sp3 protein and partially blocked the activation of the hTERT promoter by the histone deacetylase inhibitor trichostatin A. N-caproylsphingosine 44-55 Sp3 transcription factor Homo sapiens 83-86 15951564-8 2005 Mechanistically, the data demonstrated that C6-ceramide reduced the acetylation of Sp3 protein and partially blocked the activation of the hTERT promoter by the histone deacetylase inhibitor trichostatin A. N-caproylsphingosine 44-55 telomerase reverse transcriptase Homo sapiens 139-144 15563986-6 2004 The application of 1 microM C6-ceramide for 36 h reduced PPARgamma mRNA level, aP2 mRNA level, and PPARgamma protein level to 56.3%, 80.4% and 62.1%, respectively. N-caproylsphingosine 28-39 peroxisome proliferator activated receptor gamma Homo sapiens 57-66 15563986-6 2004 The application of 1 microM C6-ceramide for 36 h reduced PPARgamma mRNA level, aP2 mRNA level, and PPARgamma protein level to 56.3%, 80.4% and 62.1%, respectively. N-caproylsphingosine 28-39 peroxisome proliferator activated receptor gamma Homo sapiens 99-108 15563986-8 2004 Overexpression of wild type PKCzeta magnified and accelerated the effect of TNFalpha and C6-ceramide on PPARgamma mRNA levels, whereas overexpression of dominant negative PKCzeta abolished the effect. N-caproylsphingosine 89-100 protein kinase C zeta Homo sapiens 28-35 15563986-8 2004 Overexpression of wild type PKCzeta magnified and accelerated the effect of TNFalpha and C6-ceramide on PPARgamma mRNA levels, whereas overexpression of dominant negative PKCzeta abolished the effect. N-caproylsphingosine 89-100 peroxisome proliferator activated receptor gamma Homo sapiens 104-113 15474071-2 2004 DESIGN: The effects of IL-1alpha, IL-1 receptor antagonist (IL-1RA), C2-ceramide, and C6-ceramide on the production of IL-6, IL-8, and M-CSF by ESC. N-caproylsphingosine 86-97 interleukin 6 Homo sapiens 119-123 15474071-2 2004 DESIGN: The effects of IL-1alpha, IL-1 receptor antagonist (IL-1RA), C2-ceramide, and C6-ceramide on the production of IL-6, IL-8, and M-CSF by ESC. N-caproylsphingosine 86-97 colony stimulating factor 1 Homo sapiens 135-140 14622092-6 2003 The mechanism of TNFalpha-mediated neuroprotection and antagonism by nicotine was independent of caspase 8 activation or nuclear factor kappa B translocation in neurons but C6-ceramide addition to neuronal cultures subsequently exposed to NMDA mimicked the neuroprotective effect of TNFalpha and, like TNFalpha, it was antagonized by cotreatment with nicotine. N-caproylsphingosine 173-184 tumor necrosis factor Mus musculus 17-25 15474071-9 2004 Production of both IL-8 and M-CSF was statistically significantly increased by IL-1alpha plus C6-ceramide as compared with IL-1alpha alone; however, IL-6 production was not increased. N-caproylsphingosine 94-105 C-X-C motif chemokine ligand 8 Homo sapiens 19-23 15474071-9 2004 Production of both IL-8 and M-CSF was statistically significantly increased by IL-1alpha plus C6-ceramide as compared with IL-1alpha alone; however, IL-6 production was not increased. N-caproylsphingosine 94-105 colony stimulating factor 1 Homo sapiens 28-33 12569071-10 2003 Rather an involvement of the sphingolipid ceramide is likely, since IL-1beta triggers rapid ceramide formation and incubation of cells with the cell-permeable C6-ceramide blocked ATP-induced PKB phosphorylation. N-caproylsphingosine 159-170 interleukin 1 beta Homo sapiens 68-76 12576296-7 2003 Notably, overexpression of Bcl-2 reduced the basal cellular levels of ceramide and prevented the induction of ceramide generation by C(6)-ceramide, which implies ceramide generation as a possible target for the antiapoptotic effects of Bcl-2. N-caproylsphingosine 133-146 BCL2 apoptosis regulator Homo sapiens 27-32 14614956-7 2003 C6-ceramide induces TrkA phosphorylation and selective activation of the phosphatidyl inositol 3-kinase (PI3-kinase)/Akt pathway but not the MAPK/ERK pathway. N-caproylsphingosine 0-11 neurotrophic receptor tyrosine kinase 1 Rattus norvegicus 20-24 14614956-7 2003 C6-ceramide induces TrkA phosphorylation and selective activation of the phosphatidyl inositol 3-kinase (PI3-kinase)/Akt pathway but not the MAPK/ERK pathway. N-caproylsphingosine 0-11 AKT serine/threonine kinase 1 Rattus norvegicus 117-120 12515830-5 2003 Using human fibroblasts transfected with a alpha2(I) collagen promoter/reporter gene construct (COL1A2), C(6)-ceramide (10 microm) exerted a stimulatory effect on basal and TGF-beta-induced activity of this promoter. N-caproylsphingosine 105-118 collagen type I alpha 2 chain Homo sapiens 96-102 12515830-5 2003 Using human fibroblasts transfected with a alpha2(I) collagen promoter/reporter gene construct (COL1A2), C(6)-ceramide (10 microm) exerted a stimulatory effect on basal and TGF-beta-induced activity of this promoter. N-caproylsphingosine 105-118 transforming growth factor beta 1 Homo sapiens 173-181 12569071-10 2003 Rather an involvement of the sphingolipid ceramide is likely, since IL-1beta triggers rapid ceramide formation and incubation of cells with the cell-permeable C6-ceramide blocked ATP-induced PKB phosphorylation. N-caproylsphingosine 159-170 protein tyrosine kinase 2 beta Homo sapiens 191-194 12524657-7 2003 Pretreatment with C(6)-ceramide significantly reduced autophosphorylation of the IR beta-subunit, tyrosine phosphorylation of IRS-1, and enzyme activity of PI3K. N-caproylsphingosine 18-31 insulin receptor substrate 1 Rattus norvegicus 126-131 12532151-3 2003 RESULTS: C(6)-ceramide increased basal 2-deooxyglucose uptake but decreased insulin-stimulated uptake without changing the EC(50) for insulin. N-caproylsphingosine 9-22 insulin Homo sapiens 76-83 12524657-8 2003 Moreover, membrane-associated PKCzeta immunoreactivity and immunoprecipitable PKCzeta enzyme activity, downstream of PI3K, were significantly suppressed by C(6)-ceramide pretreatment. N-caproylsphingosine 156-169 protein kinase C, zeta Rattus norvegicus 30-37 12524657-8 2003 Moreover, membrane-associated PKCzeta immunoreactivity and immunoprecipitable PKCzeta enzyme activity, downstream of PI3K, were significantly suppressed by C(6)-ceramide pretreatment. N-caproylsphingosine 156-169 protein kinase C, zeta Rattus norvegicus 78-85 12413956-5 2002 Furthermore, cofilin, which is a specific substrate of LIMK-1, shows an increased phosphorylation at Ser-3 in mesangial cells exposed to C6-ceramide. N-caproylsphingosine 137-148 LIM domain kinase 1 Rattus norvegicus 55-61 12408376-9 2002 Likewise, addition of a cell-permeable form of ceramide (C6-ceramide) could mimic the effect of Cox inhibitors on both cell cycle and cell growth inhibition. N-caproylsphingosine 57-68 cytochrome c oxidase subunit 4I1 Mus musculus 96-99 12390956-6 2002 C6-ceramide stimulated eNOS transcription by a signaling mechanism involving protein phosphatase PP2A but did not modify the stability of the eNOS mRNA. N-caproylsphingosine 0-11 nitric oxide synthase 3 Homo sapiens 23-27 12390956-6 2002 C6-ceramide stimulated eNOS transcription by a signaling mechanism involving protein phosphatase PP2A but did not modify the stability of the eNOS mRNA. N-caproylsphingosine 0-11 protein phosphatase 2 phosphatase activator Homo sapiens 97-101 11441001-2 2001 C(6)-ceramide (20 microm) caused a significant reduction of telomerase activity at 24 h as detected using the telomeric repeat amplification protocol, and this inhibition correlated with decreased telomerase reverse transcriptase (hTERT) protein. N-caproylsphingosine 0-13 telomerase reverse transcriptase Homo sapiens 231-236 11723139-6 2002 We demonstrate that C(6)-ceramide (but not the inactive analog dihydro-C(6)-ceramide) induced PKCzeta activity and also caused a selective increase in the association between Akt and PKCzeta, without affecting PKCepsilon, in A7r5 cells. N-caproylsphingosine 20-33 AKT serine/threonine kinase 1 Rattus norvegicus 175-178 11723139-6 2002 We demonstrate that C(6)-ceramide (but not the inactive analog dihydro-C(6)-ceramide) induced PKCzeta activity and also caused a selective increase in the association between Akt and PKCzeta, without affecting PKCepsilon, in A7r5 cells. N-caproylsphingosine 20-33 protein kinase C, zeta Rattus norvegicus 94-101 11775008-10 2001 Both PGE2 and PGF2alpha production were significantly increased by treatment with IL-1alpha and C6-ceramide as compared with IL-1alpha treatment alone. N-caproylsphingosine 96-107 interleukin 1 alpha Homo sapiens 125-134 11697858-2 2001 Cell-permeable C(6)-ceramide (N-hexanoylsphingosine) suppressed antigen-stimulated phosphorylation of ERK1/2 and p38 mitogen-activated protein kinase. N-caproylsphingosine 15-28 mitogen activated protein kinase 3 Rattus norvegicus 102-108 11697858-2 2001 Cell-permeable C(6)-ceramide (N-hexanoylsphingosine) suppressed antigen-stimulated phosphorylation of ERK1/2 and p38 mitogen-activated protein kinase. N-caproylsphingosine 15-28 mitogen activated protein kinase 14 Rattus norvegicus 113-116 11697858-2 2001 Cell-permeable C(6)-ceramide (N-hexanoylsphingosine) suppressed antigen-stimulated phosphorylation of ERK1/2 and p38 mitogen-activated protein kinase. N-caproylsphingosine 30-51 mitogen activated protein kinase 3 Rattus norvegicus 102-108 11697858-2 2001 Cell-permeable C(6)-ceramide (N-hexanoylsphingosine) suppressed antigen-stimulated phosphorylation of ERK1/2 and p38 mitogen-activated protein kinase. N-caproylsphingosine 30-51 mitogen activated protein kinase 14 Rattus norvegicus 113-116 11677262-4 2001 C6-ceramide (30 microM) caused a 53% inhibition of I(KCa) [a component that is generated by the IBTX-sensitive K(+) channel (BK channel)], a 27% inhibition of I(A) and a 17% inhibition of I(K). N-caproylsphingosine 0-11 potassium calcium-activated channel subfamily M alpha 1 Rattus norvegicus 125-135 11441001-3 2001 Semi-quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) and Northern blot analyses showed that C(6)-ceramide significantly decreased hTERT mRNA in a time-dependent manner. N-caproylsphingosine 114-127 telomerase reverse transcriptase Homo sapiens 152-157 11441001-5 2001 Further analysis using RT-PCR and Western blotting showed that c-Myc protein but not its mRNA levels were decreased in response to C(6)-ceramide at 24 h. The effects of ceramide on the c-Myc protein were shown to be due to a reduction in half-life via increased ubiquitination. N-caproylsphingosine 131-144 MYC proto-oncogene, bHLH transcription factor Homo sapiens 63-68 11335714-8 2001 Finally, stable overexpression of human glucosylceramide synthase, which attenuates ceramide levels by converting ceramide to glucosylceramide, prevented the inhibitory effects of C(6)-ceramide and daunorubicin on telomerase. N-caproylsphingosine 180-193 UDP-glucose ceramide glucosyltransferase Homo sapiens 40-65 11259399-4 2001 Application of a novel, potent, and specific inhibitor of aSMase expression (NB6) diminished the effects of mmLDL and C6-ceramide treatment by inhibiting transcription via Sp1 and AP-2. N-caproylsphingosine 118-129 sphingomyelin phosphodiesterase 1 Homo sapiens 58-64 11259399-4 2001 Application of a novel, potent, and specific inhibitor of aSMase expression (NB6) diminished the effects of mmLDL and C6-ceramide treatment by inhibiting transcription via Sp1 and AP-2. N-caproylsphingosine 118-129 transcription factor AP-2 alpha Homo sapiens 180-184 11259399-5 2001 Moreover, apoptosis was abolished after mmLDL and C6-ceramide treatment of hereditary aSMase-deficient fibroblasts (from Niemann-Pick patients). N-caproylsphingosine 50-61 sphingomyelin phosphodiesterase 1 Homo sapiens 86-92 10915783-4 2000 C(2)- and C(6)-ceramides selectively stimulated the expression of RAR-alpha and RXR-alpha genes, but not that of beta and gamma isoform genes of RAR and RXR, in the cells. N-caproylsphingosine 10-24 retinoic acid receptor, alpha Mus musculus 66-75 11361017-7 2001 Similar to Pc 4-PDT, exogenous C6-ceramide bypassed FADD deficiency and induced zVAD-sensitive apoptosis. N-caproylsphingosine 31-42 SUB1 homolog, transcriptional regulator Mus musculus 11-15 11068881-2 2000 Pretreatment of platelets with sphingomyelinase or C6-ceramide (N-hexanoylsphingosine) led to apparent enhancement of Ca2+-ionophore A23187-stimulated arachidonic acid release but did not affect the cytosolic phospholipase A2 (cPLA2) activity. N-caproylsphingosine 51-62 phospholipase A2 group IVA Homo sapiens 199-225 11068881-2 2000 Pretreatment of platelets with sphingomyelinase or C6-ceramide (N-hexanoylsphingosine) led to apparent enhancement of Ca2+-ionophore A23187-stimulated arachidonic acid release but did not affect the cytosolic phospholipase A2 (cPLA2) activity. N-caproylsphingosine 51-62 phospholipase A2 group IVA Homo sapiens 227-232 11068881-2 2000 Pretreatment of platelets with sphingomyelinase or C6-ceramide (N-hexanoylsphingosine) led to apparent enhancement of Ca2+-ionophore A23187-stimulated arachidonic acid release but did not affect the cytosolic phospholipase A2 (cPLA2) activity. N-caproylsphingosine 64-85 phospholipase A2 group IVA Homo sapiens 199-225 11068881-2 2000 Pretreatment of platelets with sphingomyelinase or C6-ceramide (N-hexanoylsphingosine) led to apparent enhancement of Ca2+-ionophore A23187-stimulated arachidonic acid release but did not affect the cytosolic phospholipase A2 (cPLA2) activity. N-caproylsphingosine 64-85 phospholipase A2 group IVA Homo sapiens 227-232 11068881-4 2000 Sphingomyelinase and C6-ceramide, but not C6-dihydroceramide, a control analog of C6-ceramide, also facilitated the Ca2+-dependent increase in the cPLA2 protein, as well as the activity, in membranes induced by addition of Ca2+ into platelet lysate. N-caproylsphingosine 21-32 phospholipase A2 group IVA Homo sapiens 147-152 10915783-4 2000 C(2)- and C(6)-ceramides selectively stimulated the expression of RAR-alpha and RXR-alpha genes, but not that of beta and gamma isoform genes of RAR and RXR, in the cells. N-caproylsphingosine 10-24 retinoid X receptor alpha Mus musculus 80-89 10915783-4 2000 C(2)- and C(6)-ceramides selectively stimulated the expression of RAR-alpha and RXR-alpha genes, but not that of beta and gamma isoform genes of RAR and RXR, in the cells. N-caproylsphingosine 10-24 retinoic acid receptor, alpha Mus musculus 66-69 10788440-5 2000 Addition of cell-permeable ceramide analogs, C(2)- or C(6)-ceramide, caused a partial loss (50-60%) of PKB activation. N-caproylsphingosine 54-67 protein tyrosine kinase 2 beta Homo sapiens 103-106 10514462-6 1999 Although production of hydrogen peroxide was increased by either C(6)-ceramide or TNF-alpha in Bcl-2 negative Daudi cells commensurate with the early phases of apoptosis, this increase did not occur in Bcl-2-expressing cells. N-caproylsphingosine 65-78 BCL2 apoptosis regulator Homo sapiens 95-100 10766421-3 2000 We demonstrated that treatment of HL-60 cells with C6-ceramide resulted in G1 phase elevation followed by apoptotic cleavage associated with increase in the level of cdk inhibitor p27(kip1). N-caproylsphingosine 51-62 zinc ribbon domain containing 2 Homo sapiens 180-183 10766421-3 2000 We demonstrated that treatment of HL-60 cells with C6-ceramide resulted in G1 phase elevation followed by apoptotic cleavage associated with increase in the level of cdk inhibitor p27(kip1). N-caproylsphingosine 51-62 cyclin dependent kinase inhibitor 1B Homo sapiens 184-188 10702281-11 2000 GCS antisense transfected cells were also 2.4-fold more sensitive to C(6)-ceramide compared with parental cells (EC(50) = 4. N-caproylsphingosine 69-82 UDP-glucose ceramide glucosyltransferase Homo sapiens 0-3 10559283-11 1999 C(6)-ceramide, fumonisin B(1) (FB(1)), or etoposide was used to initiate PCD following transfection of cells with plasmids expressing LR gene products and the beta-galactosidase gene. N-caproylsphingosine 0-13 galactosidase beta 1 Homo sapiens 159-177 10669928-4 1999 The PCNA expression was downregulated in a dose-dependent manner after treatment with C6-ceramide. N-caproylsphingosine 86-97 proliferating cell nuclear antigen Homo sapiens 4-8 10714936-8 2000 The induction of beta-Gal expression is specific to C6-ceramide. N-caproylsphingosine 52-63 galactosidase beta 1 Homo sapiens 17-25 10403818-2 1999 Increasing the ceramide content of keratinocytes with Smase (100 U/ml) or C6-ceramide (1 microM) enhanced matrix metalloproteinase (MMP)-9 production. N-caproylsphingosine 74-85 matrix metallopeptidase 9 Homo sapiens 106-138 10447683-3 1999 Addition of short-chain C6-ceramide to the cells resulted in a dose- and time-dependent inhibition of the CDP-pathways for PtdCho and PtdEtn synthesis. N-caproylsphingosine 24-35 cut-like homeobox 1 Rattus norvegicus 106-109 10447683-7 1999 In pulse-chase experiments, radioactive choline and ethanolamine accumulated in CDP-choline and CDP-ethanolamine under the influence of C6-ceramide, suggesting that synthesis of both PtdCho and PtdEtn were inhibited at the final step in the CDP-pathways. N-caproylsphingosine 136-147 cut-like homeobox 1 Rattus norvegicus 80-83 10447683-7 1999 In pulse-chase experiments, radioactive choline and ethanolamine accumulated in CDP-choline and CDP-ethanolamine under the influence of C6-ceramide, suggesting that synthesis of both PtdCho and PtdEtn were inhibited at the final step in the CDP-pathways. N-caproylsphingosine 136-147 cut-like homeobox 1 Rattus norvegicus 96-99 10447683-7 1999 In pulse-chase experiments, radioactive choline and ethanolamine accumulated in CDP-choline and CDP-ethanolamine under the influence of C6-ceramide, suggesting that synthesis of both PtdCho and PtdEtn were inhibited at the final step in the CDP-pathways. N-caproylsphingosine 136-147 cut-like homeobox 1 Rattus norvegicus 96-99 10447683-10 1999 It was concluded that C6-ceramide affected glycerophospholipid synthesis predominantly by inhibition of the step in the CDP-pathways catalysed by cholinephosphotransferase and ethanolaminephosphotransferase. N-caproylsphingosine 22-33 cut-like homeobox 1 Rattus norvegicus 120-123 9950688-10 1999 This perinuclear AE1-containing compartment is also stained by ankyrin antibodies and partially overlaps the membrane compartment stained by NBD C6-ceramide, a Golgi marker. N-caproylsphingosine 145-156 solute carrier family 4 member 1 (Diego blood group) Gallus gallus 17-20 9880803-1 1999 To study the involvement of sphingolipids in glycerophospholipid metabolism, the contribution of ceramide to the activation of group IV cytosolic phospholipase A2 (cPLA2) was investigated in platelets using cell-permeable C6-ceramide (N-hexanoylsphingosine). N-caproylsphingosine 222-233 cytosolic phospholipase A2 Oryctolagus cuniculus 164-169 9880803-1 1999 To study the involvement of sphingolipids in glycerophospholipid metabolism, the contribution of ceramide to the activation of group IV cytosolic phospholipase A2 (cPLA2) was investigated in platelets using cell-permeable C6-ceramide (N-hexanoylsphingosine). N-caproylsphingosine 235-256 cytosolic phospholipase A2 Oryctolagus cuniculus 164-169 9556209-2 1998 When washed rabbit platelets were pretreated with ceramide and then stimulated with thrombin or U46619, C2-ceramide (N-acetylsphingosine) dose-dependently inhibited the aggregation and arachidonic acid liberation, whereas C6-ceramide (N-hexanoylsphingosine) and C8-ceramide (N-octanoylsphingosine) enhanced these responses. N-caproylsphingosine 222-233 prothrombin Oryctolagus cuniculus 84-92 9719464-5 1998 This apoptotic cell death with p21 induction was also observed in the Hep 3B cells lacking functional p53 after exposure to C6-ceramide. N-caproylsphingosine 124-135 H3 histone pseudogene 16 Homo sapiens 31-34 9719464-5 1998 This apoptotic cell death with p21 induction was also observed in the Hep 3B cells lacking functional p53 after exposure to C6-ceramide. N-caproylsphingosine 124-135 tumor protein p53 Homo sapiens 102-105 9556209-2 1998 When washed rabbit platelets were pretreated with ceramide and then stimulated with thrombin or U46619, C2-ceramide (N-acetylsphingosine) dose-dependently inhibited the aggregation and arachidonic acid liberation, whereas C6-ceramide (N-hexanoylsphingosine) and C8-ceramide (N-octanoylsphingosine) enhanced these responses. N-caproylsphingosine 235-256 prothrombin Oryctolagus cuniculus 84-92 9314949-4 1997 C6-ceramide (cer) can also sensitize EC to TNF-induced apoptosis. N-caproylsphingosine 0-11 tumor necrosis factor Homo sapiens 43-46 9450998-7 1998 Both TNF and exogeneous C6-ceramide interfered with the mitogenic activation of Raf-1 and ERK by epidermal growth factor and down-regulated v-Src-induced Raf-1 kinase activity. N-caproylsphingosine 24-35 Raf-1 proto-oncogene, serine/threonine kinase Homo sapiens 80-85 9450998-7 1998 Both TNF and exogeneous C6-ceramide interfered with the mitogenic activation of Raf-1 and ERK by epidermal growth factor and down-regulated v-Src-induced Raf-1 kinase activity. N-caproylsphingosine 24-35 mitogen-activated protein kinase 1 Homo sapiens 90-93 9450998-7 1998 Both TNF and exogeneous C6-ceramide interfered with the mitogenic activation of Raf-1 and ERK by epidermal growth factor and down-regulated v-Src-induced Raf-1 kinase activity. N-caproylsphingosine 24-35 epidermal growth factor Homo sapiens 97-120 9450998-7 1998 Both TNF and exogeneous C6-ceramide interfered with the mitogenic activation of Raf-1 and ERK by epidermal growth factor and down-regulated v-Src-induced Raf-1 kinase activity. N-caproylsphingosine 24-35 SRC proto-oncogene, non-receptor tyrosine kinase Homo sapiens 142-145 9450998-7 1998 Both TNF and exogeneous C6-ceramide interfered with the mitogenic activation of Raf-1 and ERK by epidermal growth factor and down-regulated v-Src-induced Raf-1 kinase activity. N-caproylsphingosine 24-35 Raf-1 proto-oncogene, serine/threonine kinase Homo sapiens 154-159 9468284-1 1998 We demonstrate a rapid and transient activation of phosphoinositide-3-kinase (PI-3-K) by Fas receptor triggering or cellular treatment with synthetic C6-ceramide. N-caproylsphingosine 150-161 phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta Homo sapiens 51-76 9314949-4 1997 C6-ceramide (cer) can also sensitize EC to TNF-induced apoptosis. N-caproylsphingosine 3-6 tumor necrosis factor Homo sapiens 43-46 9207149-3 1997 Tyrosine phosphorylation of the n-K+ channel correlated with an activation of the Src-like tyrosine kinase p56lck upon cellular treatment with the ceramide analog C6-ceramide. N-caproylsphingosine 163-174 LCK proto-oncogene, Src family tyrosine kinase Homo sapiens 107-113 9268362-1 1997 In the present study, we show that Fas receptor ligation or cellular treatment with synthetic C6-ceramide results in activation or phosphorylation, respectively, of the small G-protein Rac1, Jun N-terminal kinase (JNK)/p38 kinases (p38-K), and the transcription factor GADD153. N-caproylsphingosine 94-105 Rac family small GTPase 1 Homo sapiens 185-189 9268362-1 1997 In the present study, we show that Fas receptor ligation or cellular treatment with synthetic C6-ceramide results in activation or phosphorylation, respectively, of the small G-protein Rac1, Jun N-terminal kinase (JNK)/p38 kinases (p38-K), and the transcription factor GADD153. N-caproylsphingosine 94-105 mitogen-activated protein kinase 8 Homo sapiens 191-212 9268362-1 1997 In the present study, we show that Fas receptor ligation or cellular treatment with synthetic C6-ceramide results in activation or phosphorylation, respectively, of the small G-protein Rac1, Jun N-terminal kinase (JNK)/p38 kinases (p38-K), and the transcription factor GADD153. N-caproylsphingosine 94-105 mitogen-activated protein kinase 8 Homo sapiens 214-217 9268362-1 1997 In the present study, we show that Fas receptor ligation or cellular treatment with synthetic C6-ceramide results in activation or phosphorylation, respectively, of the small G-protein Rac1, Jun N-terminal kinase (JNK)/p38 kinases (p38-K), and the transcription factor GADD153. N-caproylsphingosine 94-105 mitogen-activated protein kinase 14 Homo sapiens 219-222 9268362-1 1997 In the present study, we show that Fas receptor ligation or cellular treatment with synthetic C6-ceramide results in activation or phosphorylation, respectively, of the small G-protein Rac1, Jun N-terminal kinase (JNK)/p38 kinases (p38-K), and the transcription factor GADD153. N-caproylsphingosine 94-105 mitogen-activated protein kinase 14 Homo sapiens 232-235 9268362-1 1997 In the present study, we show that Fas receptor ligation or cellular treatment with synthetic C6-ceramide results in activation or phosphorylation, respectively, of the small G-protein Rac1, Jun N-terminal kinase (JNK)/p38 kinases (p38-K), and the transcription factor GADD153. N-caproylsphingosine 94-105 DNA damage inducible transcript 3 Homo sapiens 269-276 9210401-7 1997 Moreover, C6-ceramide largely prevented the accumulation of ODC mRNA and its precursor, ODC heterogeneous nuclear RNA, that accompanied the induction of ODC activity. N-caproylsphingosine 10-21 ornithine decarboxylase, structural 1 Mus musculus 60-63 9202042-7 1997 C6-ceramide overcame the resistance to TNFalpha and caused cell death in C12 cells to a level similar to that in L929 cells. N-caproylsphingosine 0-11 tumor necrosis factor Mus musculus 39-47 9092523-16 1997 In this study, these bcl-xL transfectants also displayed increased resistance to exogenous N-acetylsphingosine (C2-ceramide) or N-hexanoylsphingosine (C6-ceramide). N-caproylsphingosine 128-149 BCL2-like 1 Mus musculus 21-27 9092523-16 1997 In this study, these bcl-xL transfectants also displayed increased resistance to exogenous N-acetylsphingosine (C2-ceramide) or N-hexanoylsphingosine (C6-ceramide). N-caproylsphingosine 151-162 BCL2-like 1 Mus musculus 21-27 9054379-8 1997 Furthermore, the TNF-resistant cells tested could be induced to undergo cell death after exposure to exogenous SMase or cell-permeable C6-ceramide. N-caproylsphingosine 135-146 tumor necrosis factor Homo sapiens 17-20 8870666-3 1996 In the same manner as with TNF, treatment of the adipocytes with 1-3 microM C6-ceramide, a membrane-permeable analogue of ceramide, decreased GLUT4 mRNA content by approximately 60%. N-caproylsphingosine 76-87 tumor necrosis factor Homo sapiens 27-30 9210401-7 1997 Moreover, C6-ceramide largely prevented the accumulation of ODC mRNA and its precursor, ODC heterogeneous nuclear RNA, that accompanied the induction of ODC activity. N-caproylsphingosine 10-21 ornithine decarboxylase, structural 1 Mus musculus 88-91 9210401-7 1997 Moreover, C6-ceramide largely prevented the accumulation of ODC mRNA and its precursor, ODC heterogeneous nuclear RNA, that accompanied the induction of ODC activity. N-caproylsphingosine 10-21 ornithine decarboxylase, structural 1 Mus musculus 88-91 9210401-10 1997 However, only the binding of Myc/Max was negatively affected by the treatment with C6-ceramide. N-caproylsphingosine 83-94 myelocytomatosis oncogene Mus musculus 29-32 9210401-11 1997 Furthermore, the amount of immunoreactive c-Myc, which increased after stimulation of the cells to growth, was strongly reduced by C6-ceramide. N-caproylsphingosine 131-142 myelocytomatosis oncogene Mus musculus 44-47 8870666-3 1996 In the same manner as with TNF, treatment of the adipocytes with 1-3 microM C6-ceramide, a membrane-permeable analogue of ceramide, decreased GLUT4 mRNA content by approximately 60%. N-caproylsphingosine 76-87 solute carrier family 2 member 4 Homo sapiens 142-147 8870666-4 1996 Subsequent investigations revealed that transcription of the GLUT4 gene was reduced by approximately 65% in response to C6-ceramide, demonstrating that the decrease in mRNA content is mediated by a reduction in the transcription of the genc. N-caproylsphingosine 120-131 solute carrier family 2 member 4 Homo sapiens 61-66 8702918-2 1996 Sphingomyelin hydrolysis in response to TNFalpha or bacterial SMase resulted in a time-dependent decrease in the phosphorylation state of c-Jun protein, an effect that was also observed in cells treated with the membrane-permeable ceramide analogue N-hexanoylsphingosine (C6-ceramide). N-caproylsphingosine 249-270 tumor necrosis factor Homo sapiens 40-48 8798752-3 1996 C6-Ceramide completely inhibited PLD activation after 4 h of treatment and was maximally active at 10 microM. N-caproylsphingosine 0-11 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 33-36 8798752-9 1996 Recombinant ARF plus PKCalpha substituted for crude cytosol in the activation of PLD, and this activity was inhibited by C6-ceramide. N-caproylsphingosine 121-132 protein kinase C alpha Homo sapiens 21-29 8798752-9 1996 Recombinant ARF plus PKCalpha substituted for crude cytosol in the activation of PLD, and this activity was inhibited by C6-ceramide. N-caproylsphingosine 121-132 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 81-84 8702918-2 1996 Sphingomyelin hydrolysis in response to TNFalpha or bacterial SMase resulted in a time-dependent decrease in the phosphorylation state of c-Jun protein, an effect that was also observed in cells treated with the membrane-permeable ceramide analogue N-hexanoylsphingosine (C6-ceramide). N-caproylsphingosine 249-270 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 138-143 8702918-2 1996 Sphingomyelin hydrolysis in response to TNFalpha or bacterial SMase resulted in a time-dependent decrease in the phosphorylation state of c-Jun protein, an effect that was also observed in cells treated with the membrane-permeable ceramide analogue N-hexanoylsphingosine (C6-ceramide). N-caproylsphingosine 272-283 tumor necrosis factor Homo sapiens 40-48 8702918-2 1996 Sphingomyelin hydrolysis in response to TNFalpha or bacterial SMase resulted in a time-dependent decrease in the phosphorylation state of c-Jun protein, an effect that was also observed in cells treated with the membrane-permeable ceramide analogue N-hexanoylsphingosine (C6-ceramide). N-caproylsphingosine 272-283 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 138-143 8702918-3 1996 The rapid dephosphorylation of the c-Jun gene product in response to TNFalpha, SMase, or C6-ceramide was not observed in A431 cells treated with the serine-threonine phosphatase inhibitor okadaic acid. N-caproylsphingosine 89-100 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 35-40 8641202-2 1996 In FSH-treated cells, IL1 beta (0.3-30 ng/ml) inhibited progesterone biosynthesis in a dose-dependent manner, an effect that was also observed in cells exposed to increasing concentrations of bacterial SMase (0.003-0.3 U/ml) or the membrane-permeable ceramide analogue N-hexanoylsphingosine (C6-cer:0.1-10 microM). N-caproylsphingosine 269-290 interleukin 1 beta Homo sapiens 22-30 8641202-2 1996 In FSH-treated cells, IL1 beta (0.3-30 ng/ml) inhibited progesterone biosynthesis in a dose-dependent manner, an effect that was also observed in cells exposed to increasing concentrations of bacterial SMase (0.003-0.3 U/ml) or the membrane-permeable ceramide analogue N-hexanoylsphingosine (C6-cer:0.1-10 microM). N-caproylsphingosine 292-298 interleukin 1 beta Homo sapiens 22-30 8662781-13 1996 C6-ceramide inhibited basal and PMA-induced phosphorylation of PKCalpha. N-caproylsphingosine 0-11 protein kinase C alpha Homo sapiens 63-71 7742354-3 1995 Acyl-CoA:cholesterol acyltransferase (ACAT) in CHO cells was inhibited rapidly (< 30 min) and in a dose-dependent fashion by two N-acyl analogues of naturally occurring D-erythro-ceramide, N-acetyl-sphingosine (D-erythro-C2-ceramide) and N-hexanoyl-sphingosine (D-erythro-C6-ceramide). N-caproylsphingosine 241-263 sterol O-acyltransferase 1 Cricetulus griseus 0-36 8662781-6 1996 Exposure of Molt-4 cells to C6-ceramide resulted in a concentration and time-dependent inhibition of immunoprecipitated protein kinase Calpha (PKCalpha). N-caproylsphingosine 28-39 protein kinase C alpha Homo sapiens 143-151 8662781-7 1996 Initial inhibition was observed as early as 4.5 h after treatment of cells with C6-ceramide, and the activity was completely lost by 13 h. Inhibition of PKCalpha activity was seen at concentrations of ceramide as low as 5 microM with maximal effects occurring at a concentration of 15 microM. N-caproylsphingosine 80-91 protein kinase C alpha Homo sapiens 153-161 8555272-5 1996 Though less potent than C2-ceramide, C6-ceramide (N-hexanoylsphingosine) could prime for O2- generated in response to 0.1 microM fMLP, with maximal effects obtained at 10-20 microM. N-caproylsphingosine 37-48 formyl peptide receptor 1 Homo sapiens 129-133 8555272-5 1996 Though less potent than C2-ceramide, C6-ceramide (N-hexanoylsphingosine) could prime for O2- generated in response to 0.1 microM fMLP, with maximal effects obtained at 10-20 microM. N-caproylsphingosine 50-71 formyl peptide receptor 1 Homo sapiens 129-133 7607324-3 1995 Generation of beta-cell ceramide by exogenous sphingomyelinase, or addition of cell-permeant ceramide analogs C2-ceramide and C6-ceramide, caused inhibitor effects on beta-cell insulin production and mitogenesis mimicing those evoked by IL-1 beta. N-caproylsphingosine 126-137 insulin Homo sapiens 177-184 7621875-4 1995 C6-ceramide, mimicked the CD28 signal by inducing T cell proliferation and interleukin-2 gene transcription. N-caproylsphingosine 0-11 CD28 molecule Homo sapiens 26-30 7621875-4 1995 C6-ceramide, mimicked the CD28 signal by inducing T cell proliferation and interleukin-2 gene transcription. N-caproylsphingosine 0-11 interleukin 2 Homo sapiens 75-88 7742354-3 1995 Acyl-CoA:cholesterol acyltransferase (ACAT) in CHO cells was inhibited rapidly (< 30 min) and in a dose-dependent fashion by two N-acyl analogues of naturally occurring D-erythro-ceramide, N-acetyl-sphingosine (D-erythro-C2-ceramide) and N-hexanoyl-sphingosine (D-erythro-C6-ceramide). N-caproylsphingosine 241-263 sterol O-acyltransferase 1 Cricetulus griseus 38-42 7929315-12 1994 A soluble analog of ceramide, C6-ceramide, was found to inhibit serum-stimulated DAG accumulation and PLD activation in young cells. N-caproylsphingosine 30-41 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 102-105 34207464-0 2021 The Enhanced Efficacy of Intracellular Delivery of Doxorubicin/C6-Ceramide Combination Mediated by the F3 Peptide/Nucleolin System Is Supported by the Downregulation of the PI3K/Akt Pathway. N-caproylsphingosine 63-74 nucleolin Homo sapiens 114-123 18698493-5 2008 Neuraminidase treatment or knockdown by siRNA of uridine diphosphate-N-acetylglucosamine 2-epimerase (UDP-GlcNAc2-epimerase), which is a key enzyme of sialic acid biosynthesis, enhanced the amount of cell death induced by C6-ceramide in the highly sialylated 3G3 clone. N-caproylsphingosine 222-233 neuraminidase 1 Homo sapiens 0-13 34207464-0 2021 The Enhanced Efficacy of Intracellular Delivery of Doxorubicin/C6-Ceramide Combination Mediated by the F3 Peptide/Nucleolin System Is Supported by the Downregulation of the PI3K/Akt Pathway. N-caproylsphingosine 63-74 AKT serine/threonine kinase 1 Homo sapiens 178-181 34207464-3 2021 The underlying molecular mechanism of action of the nucleolin-mediated intracellular delivery of C6-ceramide to cancer cells was also explored. N-caproylsphingosine 97-108 nucleolin Homo sapiens 52-61 34207464-8 2021 The enhanced cytotoxicity of the targeted combination was mechanistically supported by the downregulation of PI3K/Akt pathway by C6-ceramide, only among the nucleolin-overexpressing cancer cells presenting a basal p-Akt/total Akt ratio lower than 1. N-caproylsphingosine 129-140 AKT serine/threonine kinase 1 Homo sapiens 114-117 34207464-8 2021 The enhanced cytotoxicity of the targeted combination was mechanistically supported by the downregulation of PI3K/Akt pathway by C6-ceramide, only among the nucleolin-overexpressing cancer cells presenting a basal p-Akt/total Akt ratio lower than 1. N-caproylsphingosine 129-140 AKT serine/threonine kinase 1 Homo sapiens 216-219 34207464-8 2021 The enhanced cytotoxicity of the targeted combination was mechanistically supported by the downregulation of PI3K/Akt pathway by C6-ceramide, only among the nucleolin-overexpressing cancer cells presenting a basal p-Akt/total Akt ratio lower than 1. N-caproylsphingosine 129-140 AKT serine/threonine kinase 1 Homo sapiens 226-229 35294071-0 2022 Nanoliposome C6-Ceramide in combination with anti-CTLA4 antibody improves anti-tumor immunity in hepatocellular cancer. N-caproylsphingosine 13-24 cytotoxic T-lymphocyte associated protein 4 Homo sapiens 50-55 35104605-6 2022 This effect was supported by the downregulation of the PI3K/Akt pathway enabled by C6-ceramide and in contrast with C18-ceramide. N-caproylsphingosine 83-94 AKT serine/threonine kinase 1 Homo sapiens 60-63